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hypothesis, we studied plaque formation in APPPS1 mice 
using in vivo two-photon microscopy and immunohisto-
chemical analysis. We used sequential pre- and post-mor-
tem staining techniques to label plaques at different stages 
of development and to detect newly emerged plaques. Post-
mortem analysis revealed that a subset (22 %) of newly 
formed plaques appeared very close (<40 μm) to pre-exist-
ing plaques and that many close plaques (25 %) that were 
initially separate merged over time to form one single large 
plaque. Our results suggest that small plaques can cluster 
together, thus forming larger plaques as a complementary 
mechanism to simple uniform plaque growth from a single 
initial plaque. This study deepens our understanding of Aβ 
deposition and demonstrates that there are multiple mecha-
nisms at play in plaque development.
Keywords Alzheimer’s disease · Amyloid plaques · 
APPPS1 transgenic mice · Two-photon in vivo imaging
Introduction
Amyloid-β (Aβ) plaques are a major pathological hallmark 
of AD. Although plaque deposition is not thought to cor-
relate with disease severity [12], there are numerous stud-
ies proving that the microenvironment around plaques is 
affected. For example, there is considerable evidence for 
altered neuronal structure and function in AD, such as the 
occurrence of hyperactive neurons, neuritic dystrophies 
and the loss of synapses which are almost exclusively 
observed within the peri-plaque region [5, 8, 18, 19, 23, 
28, 31]. These data emphasize the potential pathological 
importance of plaques for the disease and that plaques do 
not have a mere epiphenomenal role and, therefore, warrant 
further scientific investigation.
Abstract Amyloid-β (Aβ) plaque deposition plays a cen-
tral role in the pathogenesis of Alzheimer’s disease (AD). 
Post-mortem analysis of plaque development in mouse 
models of AD revealed that plaques are initially small, 
but then increase in size and become more numerous with 
age. There is evidence that plaques can grow uniformly 
over time; however, a complementary hypothesis of plaque 
development is that small plaques cluster and grow together 
thereby forming larger plaques. To investigate the latter 
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Previous post-mortem analyses of brain sections from 
an AD mouse model at different time points showed that 
plaques become larger on average over time with increas-
ing pathology progression [27]. Post-mortem analyses of 
brain sections from AD patients revealed variable plaque 
size in individuals. No change in plaque size occurred 
with increasing duration of disease, consistent with pro-
cesses that halt plaque growth over time. Interestingly, 
a strong correlation between earlier age of disease onset 
and larger plaque size distribution was noted, suggesting 
that individual factors that impact rapidity or frequency 
of plaque deposition might also impact their ultimate size 
[29].
Our current study reexamines the question of how these 
large plaques form. In vivo two-photon imaging revealed 
that plaques can develop rapidly de novo within 24 h and 
remain relatively small and at a stable size for at least 2 
subsequent weeks [24]. Long-term in vivo imaging stud-
ies of plaques over several months demonstrated a gradual 
uniform growth of amyloid-β plaques over time [7, 13]. 
These studies imply that initial plaque formation is very 
fast, followed by a gradual growth phase of individual 
plaques. An alternative model proposed that random spatial 
allocation was not sufficient to match the pattern of plaque 
distribution found in post-mortem histological tissue, but 
rather that plaques favorably emerged in the vicinity of an 
already existing plaque [32]. Inspired by these findings, we 
examined whether one mechanism that might lead to large 
plaques could be the cluster formation of pre-deposited and 
newly emerged plaques rather than uniform growth of a 
single, initial plaque.
In this study, we labeled plaques at multiple stages of 
development to test the hypothesis that new plaques prefer-
entially deposit in clusters around pre-existing plaques and 
to evaluate the occurrence of large plaques formed from 
multiple precursors. Our data provide the first direct in vivo 
evidence of plaque growth resulting from consolidation of 
clusters of multiple plaques.
Materials and methods
Animals
For this study, we used male heterozygous APPPS1 trans-
genic mice [27], expressing human APPKM670/671NL and 
PS1L166P under the control of the Thy-1 promoter [2]. 
Mice were group housed under specific pathogen-free 
conditions. Animals had access to food and water ad libi-
tum and were kept under a 12/12 h light–dark cycle. All 
animal procedures were carried out in accordance with 
an animal protocol approved by the government of Upper 
Bavaria.
Pre-mortem staining of amyloid plaques
For pre-mortem plaque labeling, we chose Methoxy-XO4 
(Neuroptix, Acton, MA, USA), a congo-red derivative, 
which has been shown to readily cross the blood brain 
barrier [16], bind to dense core plaques and importantly, 
remain bound to them for a period of at least 90 days [9]. 
Methoxy-XO4 was administered intraperitoneally (i.p.) at 
a concentration of 3.33 mg/kg (3.3 % volume of 10 mg/ml 
stock solution in DMSO (light shielded), 6.66 % volume 
Cremophore EL (Sigma Aldrich, St. Louis, MO, USA) in 
90 % volume phosphate buffered saline (PBS)) [16] to the 
mice to label the cerebral amyloid plaques present at day 
0. After different post-injection intervals of 1 day, 1 month 
or 4 months, we performed either acute in vivo two-
photon imaging or post-mortem analysis. Animals were 
all 3 months old at the time of Methoxy-XO4 injection, 
apart from one group of animals (n = 4) that was injected 
at 2 months of age followed by a post-injection time of 
2 weeks. A complete list with the number of animals used 
for each experiment is listed in Suppl. Table 1.
Cranial window surgery and two-photon in vivo imaging
The mice were anaesthetized with an i.p. injection of a 
mixture of Ketamine (10 mg/kg) and Xylazine (20 mg/
kg). Under semi-sterile conditions, a cranial window was 
implanted as previously described [14, 31]. Briefly, a 6 mm 
diameter circle of cranial bone was removed using a micro 
drill (Stoelting, Wood dale, IL, USA) over the parietal 
cortex and the dura mater detached [30]. 20 μl of anti-
Aβ antibody 6E10 (Sigma Aldrich, St. Louis, MO, USA) 
covalently labeled with Alexa 594 (antibody labeling kit, 
InvivoGen, San Diago, CA, USA) was topically applied to 
the surface of the brain for 30 min followed by two 30 min 
washes with sterile PBS. An 8 mm round glass cover slip 
was mounted over the exposed brain using Pattex Ultra 
gel (Henkel, Duesseldorf, Germany) and Paladur dental 
cement (Heraeus, South Bend, IN, USA) to close the crani-
otomy, with Paladur built up around the window to provide 
a well for the water immersion objective. Acute two-pho-
ton imaging was carried out immediately using Olympus 
FV1000 with Mai Tai Deep See Laser (Spectra Physics, 
Newport Corporation, Franklin, MA, USA) with an excita-
tion wavelength of 850 nm. Emission filters of 420–500 nm 
(Methoxy-XO4) and 590–650 nm (Alexa 594) were used. 
To visualize the deposition of new plaques, we used an 
Olympus 20× water immersion objective to acquire image 
stacks of 634 × 634 × 150 μm (xyz dimensions) with 
5 μm z-increments and 512 × 512 pixel resolution. Cor-
tical tissue immediately underneath the surface was not 
included in the analysis due to potential contamination of 
non-amyloidogenic autofluorescence signals derived from 
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blood or bone marrow cells. Following acute imaging, mice 
were killed via cervical dislocation and the brains pro-
cessed for post-mortem analysis. For chronic in vivo imag-
ing, APPPS1/GFP transgenic mice at the age of 2.5 months 
were implanted with a cranial window as described above, 
without application of the antibody and the dura mater left 
intact. After a recovery period of 4 weeks, successive Aβ 
plaque imaging of the same regions was carried out weekly 
for 1 month. Mice were re-imaged after 4 and 5.5 months. 
Methoxy-XO4 (3.3 mg/kg) was administered i.p. 24 h prior 
to each imaging session.
Post-mortem analysis
Brains were removed from the skull and fixed in 4 % 
paraformaldehyde (Roth Roti®-Histofix, Karlsruhe, Ger-
many) for 48 h, followed by incubation in 30 % sucrose 
(in PBS, pH 7.5) for a further 48 h. The brains were fro-
zen and 25 μm thick coronal frozen sections were cut 
with a sliding microtome (SM200R, Leica Biosystems, 
Wetzlar, Germany). Immunofluorescent staining was per-
formed on every tenth section with the anti-Aβ antibody 
3552 ([25]; 1:3,000, overnight at 4 °C; anti-rabbit sec-
ondary antibodies (Invitrogen, Life Technologies, Pais-
ley, UK): Alexa555, 1:1,000 1 h at room temperature or 
Alexa488, 1:250, 1 h at room temperature) or anti-Aβ 
antibody 4G8 (Covance, 1:150, overnight at 4 °C; anti-
mouse secondary antibody Alexa488 (Invitrogen), 1:250, 
1 h at room temperature). Omission of primary antibodies 
showed no detectable staining. Alternatively, dense core 
plaques were stained with Thiazin Red (Sigma Aldrich, 
2 μM solution in PBS) for 20 min at room temperature 
followed by 3 × 5 min PBS washes. Post-mortem Meth-
oxy-XO4 staining was carried out following imaging of 
pre-mortem Methoxy-XO4 labeling: the cover slip was 
removed and the mounted sections washed in PBS and 
incubated in a solution containing 100 μM Methoxy-
XO4 dissolved in 40 % ethanol (adjusted to pH 10) for 
10 min. The slide was then briefly dipped in water five 
times, put in 0.2 % NaOH in 80 % ethanol for 2 min and 
washed again in water for 10 min. Sections were mounted 
on object slides using Aqua-Poly-mount mounting media 
(PolySciences, Eppelheim, Germany). Post-mortem mul-
tichannel images were taken using an Olympus BX61 
(Olympus, Tokyo, Japan) fluorescent microscope with an 
EXFO-Xcite laser. A 20× UPLSAPO air objective and 
the following filters were used: U-MNUA (for Methoxy-
XO4 signal, excitation at 345 nm, emission at 455 nm), 
Cy3 (for the secondary antibody Alexa 555 and Thia-
zin Red, excitation at 550 nm, emission at 565 nm) and 
U-MNIBA (for Alexa 488, excitation at 495 nm, emission 
at 519 nm). Images (688 μm × 512 μm) were taken with 
an F-view 11FW camera (Olympus) over dorsal, lateral 
and ventral cortical regions. Six regions of interest (ROIs) 
were imaged per brain section, resulting in a total of 
89 ± 10.3 (mean ± standard deviation) ROIs per animal.
Image processing and data analysis
Image analysis was done using Photoshop CS5 (Adobe 
Systems Inc., San Jose, CA, USA). Background signal 
was manually subtracted using the linear image histogram 
tool. A ‘new’ plaque was defined as a structure being Aβ 
antibody positive but Methoxy-XO4 negative. The dis-
tance between plaques was measured between the centers 
of two plaques using ImageJ software (National Institutes 
of Health freeware). Plaques with a core to core distance 
of less than 40 μm were categorized as ‘in the vicinity’ 
of each other and if multiple (more than 1) new plaques 
were in the vicinity of a pre-existing plaque, then these 
were denoted as ‘flower plaques’ due to their appearance 
as petals around a central core. To determine the size dis-
tribution of plaques, we analyzed images after smoothing, 
thresholding and background subtraction steps in ImageJ. 
Aβ antibody fluorescence ≥30 pixels (≥5.5 μm2) was 
counted as plaques. Autofluorescent signal from particles 
of section edges were manually removed from the data set. 
Multicore plaques were classified as plaques bearing 2 or 
more, clearly separate, Methoxy-XO4 positive cores that 
were located within the boundaries of a single Aβ antibody 
labeled plaque. To determine the chance level of plaque 
deposition in close vicinity of a pre-existing plaque, we 
computer-generated new plaques in random locations using 
a custom-written program in MATLAB (Mathworks). A 
plaque-free region was chosen to estimate the level of the 
background noise. Detection stringency was set to nine 
times the standard deviation of the background noise and 
putative plaques had to consist of a minimum area of 20 
pixels (5 μm2). All imagery was visually checked for cor-
rect plaque detection. For the simulation, the same number 
of newly deposited plaques that were counted in the origi-
nal image was placed at random locations within the image, 
and their distances to the center of the closest pre-existing 
plaque determined. For each image, 1,000 iterations of the 
simulation were conducted, and the proportion of ‘new in 
vicinity’ plaques occurring by chance was compared to the 
original proportion of new plaques.
Statistics
All data sets were tested for normality with the D’Agostino-
Pearson omnibus K2 normality test with a significance 
level set to p = 0.05, before the appropriate parametric or 
non-parametric statistical comparison test was carried out 
with GraphPad Prism 5.04. (GraphPad Inc., La Jolla, CA, 
USA).
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Results
We used a two-stage staining technique with different dyes 
and antibodies to label plaques at multiple stages of plaque 
development. To label plaques at ‘day 0’, the fluorescent 
amyloid binding dye Methoxy-XO4 was used as it is a 
marker of amyloid fibrils and remains bound to plaques for 
at least 90 days in the living mouse brain [9]. Following 
a post-injection time of 1 day (1 day represents the ear-
liest possible time point for plaque analysis), 1 month or 
4 months (note that as the animals were all the same age at 
Methoxy-XO4 injection, a longer post-injection time also 
corresponds to a greater age of the animals), we visualized 
new plaques using an antibody against Aβ (Fig. 1). With 
this dual staining technique, we were able to distinguish 
pre-existing (double labeled with Methoxy-XO4 and Aβ 
antibody) from newly developed (exclusively Aβ antibody 
stained) plaques (Fig. 1). We observed these two plaque 
categories with in vivo two-photon imaging, using a topi-
cally applied antibody against Aβ (Fig. 1a–c). In vivo two-
photon imaging, however, only allows for the analysis of a 
relatively small and restricted cortical volume since anti-
body penetration is less than 200 μm and limited to the 
upper cortical layers [30]. Therefore, to gain a more com-
prehensive picture of new plaque appearance, we extended 
our study and included post-mortem brain slice analy-
sis. Consistent with an earlier study [24], we found that 
96.2 % of plaques were co-stained with Aβ antibody 1 day 
after Methoxy-XO4 injection with only negligible Aβ 
antibody positive new plaques (3.8 % ± 0.4, Fig. 1d–f). 
In contrast, numerous new plaques developed with longer 
post-injection periods (Fig. 1g–l, arrowheads). As the Aβ 
antibody labels diffuse Aβ in addition to the dense cores 
of plaques labeled by Methoxy-XO4 and may, therefore, 
label an additional population of plaques, we performed a 
post-mortem dense core stain using either Methoxy-XO4 
(Suppl. Fig. 1a–c) or Thiazin Red (Suppl. Fig. 1d–f). The 
latter affirmed that only 0.8 % of Aβ antibody positive 
plaques were not dense core positive, further validating 
our antibody staining technique. As an additional control, 
we used the monoclonal antibody 4G8 as an alternative Aβ 
staining. This antibody was shown to label best the diffuse, 
fleecy amyloid in human brain sections [1]. With both anti-
bodies (3552 and 4G8), we obtained similar results as seen 
by similar antibody labeled halo size after different post-
injection times (compare Fig. 2c, f, i with Suppl. Fig. 2d, 
h, l). The population of new plaques also included plaques 
appearing very close (<40 μm) to pre-existing plaques we 
categorized as ‘new in vicinity’ (Fig. 2c, f and i, yellow 
arrowheads). Quantification of all plaques revealed that 
longer post-injection times resulted in more new plaques, 
including more ‘new in vicinity’ plaques (Fig. 2j). The 
amount of ‘new in vicinity’ plaques consistently accounted 
for ~22 % of all new plaques, independent of the post-
injection time.
To determine if the above-mentioned 22 % of all new 
plaques found very close to pre-existing ones was not sim-
ply due to chance, we generated computer-simulated ‘new’ 
plaques in random locations and measured the distance 
of these randomly placed new plaques to already exist-
ing ones. Indeed, the amount of original ‘new in vicinity’ 
plaques was significantly higher than the random, simu-
lated new plaques (Fig. 2k). This trend held true for all 
post-injection time groups, but was only significant in the 
short post-injection group (2-month-old animals with a 
Fig. 1  Pre-existing and new plaques revealed with dual staining tech-
nique. a–c In vivo two-photon imaging of newly appearing amyloid 
plaques. Methoxy-XO4 labeled pre-existing plaques in green (a), 
anti-Aβ antibody labeled plaques after 4 months post-injection as 
shown in red (b) and the merged image of the two fluorescence chan-
nels with newly developed plaques depicted with white arrowheads 
(c). d–l Occurrence of new plaques demonstrated by sequential pre- 
and post-mortem staining. Plaques that existed at day 0 (3-month-old 
animals) are visualized with Methoxy-XO4 (d, g, j). Post-mortem 
plaque analysis with immunohistochemical staining against Aβ (e) 
reveals almost complete co-localization at 1-day post-injection (f). 
After 1 month (g–i) and 4 months post-injection (j–l), an increasing 
amount of newly formed plaques (white arrowheads), including ‘new 
in vicinity’ plaques (<40 μm away from a pre-existing plaque, yellow 
arrowheads) were detectable (i, l). MX Methoxy-XO4. Scale bar a–c 
50 μm, d–l 100 μm
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2 week post-injection time and 3 month old animals with 
a 1-day post-injection incubation time) (Suppl. Fig. 3 a). 
After 1 and 4 months post-Methoxy-XO4 injection, the 
data had the same trend—there were more ‘new in vicinity’ 
plaques in the original compared to the simulated data—
however, for these groups, this difference did not reach sig-
nificance (Suppl. Fig. 3b), most likely due to higher plaque 
density with increasing time (Suppl. Fig. 3c).
We observed that several new plaques can cluster in the 
vicinity of a single pre-existing plaque and characterized 
these clusters as ‘flower plaques’ due to their appearance of 
multiple new ‘petal’ plaques surrounding a central, Meth-
oxy-XO4 positive plaque. We defined these flower plaques 
as two or more new plaques developing <40 μm away from 
the same pre-existing plaque. We identified these flower 
plaques with two-photon in vivo imaging after topical Aβ 
antibody administration (Fig. 3a–c) as well as with post-
mortem antibody staining techniques (Fig. 3d–f). Of all 
‘new in vicinity’ plaques, 10.5 % contributed to a flower 
plaque cluster (analysis of post-mortem images). The new 
plaques (‘petals’) can be of diffuse (Fig. 3b–c, e–f, yel-
low arrowheads) as well as of dense core nature (Fig. 3h–i, 
yellow arrowheads). To exclude the possibility that these 
‘flower’ clusters were not simply an artifact caused by 
Methoxy-XO4, we stained age-matched naïve mice that 
did not receive Methoxy-XO4 prior to post-mortem stain-
ing and observed identical flower plaque structures (Suppl. 
Fig. 4a–c). To further investigate whether large plaques can 
form from multiple small precursor plaques, we analyzed 
the entire data set of plaques to find those which contained 
at least two distinct Methoxy-XO4 positive cores within an 
Aβ antibody positive plaque (≥2 separate Methoxy-XO4 
positive particles). Examples of these multicore plaques 
Fig. 2  ‘New in the vicinity’ plaques occur more frequently than 
expected by chance. (a–c) High resolution images of immunofluo-
rescent staining 1 day, 1 and 4 months post-Methoxy-XO4 injection 
reveal newly developed plaques in the vicinity (<40 μm) of a pre-
existing plaque (c, f, i, yellow arrowheads). Methoxy-XO4 shown in 
green, Aβ 3552 antibody staining shown in red. Quantification of new 
plaques showed an increase in both single new plaques further away 
(>40 μm) from pre-existing plaques and new plaques in the vicin-
ity (<40 μm) of a pre-existing plaque over time (j). Mean ± SEM, 
n = 5–6 per group; Kruskal–Wallis with Dunn’s post hoc test 
**p < 0.01. k Computer-simulated random locations of new plaques 
revealed a significantly lower fraction of ‘new plaques in vicinity’ 
compared to the original data set. Each data point represents one ani-
mal. Mean ± SEM, n = 20; Wilcoxon matched-pairs signed rank test 
**p < 0.01. Scale bar 25 μm
Fig. 3  Flower plaques—new plaques cluster around pre-existing 
plaques (a–c). Maximum intensity projections of an in vivo image 
observed with a two-photon microscope 4 months post-Methoxy-
XO4 injection (depicted in green) combined with acute topical appli-
cation of fluorescently labeled Aβ antibody 6E10 staining (depicted 
in red) (b). The yellow arrowheads (c, f and i) indicate new plaque 
‘petals’ clustering around a common pre-existing plaque creating a 
‘flower plaque’. A flower plaque observed with pre-mortem Methoxy-
XO4 and post-mortem Aβ antibody staining 4 months post-injection 
(d–f). A flower plaque visualized with post-mortem Thiazin Red 
4 months post-injection (g–i) illustrating that flower plaques can also 
be composed of multiple dense core plaques. Scale bar 25 μm
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are shown in Fig. 4a–i. We detected multicored plaques as 
early as 1 day post-Methoxy-XO4 injection (Fig. 4a–c) as 
well as in older animals (1 and 4 months post-Methoxy-
XO4 injection, Fig. 4d–j). In all groups studied, 13 % of 
all large plaques (>300 μm2) were multicored, indicating 
that this population of plaques developed from more than 
one initial plaque or a cluster of plaques within the post-
Methoxy-XO4 injection interval. Moreover, we found a 
highly significant positive correlation between the number 
of Methoxy-XO4 positive plaque cores contained within 
a plaque and the size of that plaque, showing that greater 
number of plaque cores corresponds to a larger plaque 
(Fig. 4k).
Next, we addressed the question of whether multiple 
Methoxy-XO4 positive cores within one plaque (as defined 
by Aβ antibody staining) can fuse together over time, 
thereby giving rise to one large dense core plaque. To this 
end, we investigated the fate of multicore plaques after a 
4 month post-Methoxy-XO4 injection period. We used 
Thiazin Red coupled with the Methoxy-XO4 and Aβ anti-
body staining to discern the nature of Aβ material. This tri-
ple labeling revealed that 75 % of multiple Methoxy-XO4 
cores did not fuse together, but instead remained separate in 
the Thiazin Red staining (Fig. 5a–d). Notably, the remain-
ing 25 % of multicored plaques did fuse together (Fig. 5e–
h) demonstrating that dense cores can indeed merge over 
time and can give rise to larger dense core plaques. With 
long-term in vivo imaging over 5.5 months, we witnessed 
the fusion of dense core plaque clusters into a larger core, 
confirming our finding with a different technique (Fig. 6a–
g). We also observed new dense cores emerging within the 
antibody halo of the Aβ antibody stain (Fig. 5i–l) indicating 
that multicore plaques can arise from plaques that develop 
sequentially.
In summary, our data demonstrate that new plaques can 
deposit over time in the close vicinity of an initial plaque 
and that these multiple new plaques can cluster and give 
rise to the so-called ‘flower plaques’. Furthermore, large 
plaques can contain multiple pre-existing dense cores that 
can fuse over time supporting the novel hypothesis that 
multiple, individually small plaques cluster to ultimately 
build a larger plaque (Fig. 7).
Discussion
In this study, we used pre- and post-mortem staining tech-
niques to label plaques at multiple stages of plaque devel-
opment. With this two-stage staining technique, we were 
able to visualize new plaques that had formed over time 
and reliably distinguish them from pre-existing plaques. 
Thereby, we unraveled the spatial relationship of newly 
deposited plaques to pre-existing plaques in detail. We 
made two important observations: (1) newly developed 
plaques are more likely to appear in the vicinity of pre-
existing plaques than can be attributed to pure random dep-
osition and (2) large plaques can be composed of multiple 
dense cores, indicating that these plaques are formed from 
initially small, individual plaques that clustered together 
and fused to become one larger plaque. Our data provide 
direct in vivo evidence that plaques can enlarge by form-
ing clusters of multiple plaques, implying a mechanism 
whereby the development of large plaques is attributed in 
Fig. 4  Large plaques can contain multiple dense cores at all time-
points investigated. Plaques with more than one initial dense plaque 
core as shown by in vivo Methoxy-XO4 injection, the so-called 
‘multicore plaques’, were found after 1 day (a–c), 1 month (d–f) 
and 4 months (g–i) post-injection. Pre-mortem Methoxy-XO4 labe-
ling (a, d and g) compared to post-mortem Aβ antibody staining (b, 
e and h) in the merged images (c, f and i) revealed multiple dense 
cores within one larger plaque. White arrows indicate dense cores and 
yellow arrowheads new plaques in the vicinity (<40 μm) of pre-exist-
ing plaques. j Quantification of multicored plaques reveals that they 
become more numerous with increasing post-Methoxy-XO4 injec-
tion times. Mean ± SEM, n = 5–6 Kruskal–Wallis test with Dunn’s 
post hoc test *p < 0.05. k Positive correlation between the number of 
cores and plaque size 4 months after Methoxy-XO4 injection (linear 
regression R2 = 0.07474; p < 0.0001, n = 687 plaques from 5 mice). 
Scale bar 25 μm
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part to the clustering of pre-deposited and newly depos-
ited plaques. This clustering concept unites the heretofore 
seemingly conflicting observations of little or no growth 
following the first appearance of plaques [6, 24], growth of 
plaques over extended periods of time [7, 13, 33] and an 
increasing size of plaques with age [27].
A first hint for plaque clustering came from computer 
simulations of plaque deposition, demonstrating that a mere 
random process could not account for the plaque deposition 
pattern observed in post-mortem brain sections. Rather, an 
influence of pre-existing plaques was necessary to success-
fully model the spatial pattern of plaque formation in AD 
pathology. Accordingly, simulated plaques formed prefer-
entially in the vicinity of existing plaques [32]. Additional 
support for the notion that plaques can cluster comes from 
another study showing that plaques in APP transgenic mice 
are non-randomly distributed and more concentrated in cer-
tain areas of the barrel cortex [3], which led the authors to 
suggest that neuronal architecture could determine where 
plaques deposit. A similar study discovered a correlation 
between neuronal activity and the spatial deposition of 
plaques [4]. Together, these studies imply that plaques do 
not just randomly emerge in space, supporting our finding 
that newly developed plaques form in the vicinity of exist-
ing plaques at higher than chance levels.
The computer simulation of new plaque location we 
employed as a control analysis clearly showed the same 
effect—that new plaques formed in the vicinity of exist-
ing plaques at higher than chance levels. In older mice with 
higher plaque load, we observed the same trend. However, 
Fig. 5  Fate of multicore 
plaques. Post-mortem Thiazin 
Red staining of dense core 
plaques (b, f, j) compared to 
Methoxy-XO4 pre-mortem 
staining 4 months prior to 
killing (a, e, i). Depicted are 
three different possibilities: a–d 
an example of non-merging 
multicores; e–h dense cores 
merging to a single dense core 
and i–l an example of a new 
dense core appearing within the 
diffuse halo around a pre-exist-
ing single dense core. White 
arrows point to multicores, the 
white arrowhead in j points to 
a newly developed dense core 
plaque. Scale bar 25 μm
Fig. 6  Cluster of plaques merg-
ing over time observed with in 
vivo imaging. Long-term, two-
photon in vivo imaging shows 
an initial cluster of multiple, 
separate, dense core plaques 
(white arrows, a) that can be 
followed over subsequent weeks 
(b–d) to finally merge together 
after several months (white 
arrowheads, e–g). Methoxy-
XO4 was injected 24 h before 
each imaging session. Scale bar 
20 μm
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it did not reach statistical significance. We speculate that 
this is due to an underestimation of the number of ‘new in 
vicinity’ plaques in the older animals. There are three possi-
ble explanations to consider for this. First, the large, diffuse 
Aβ positive plaque ring-like structure that develops around 
the initial plaques could well obscure any very close newly 
appeared plaques. Second, we also observed clusters of 
plaques within the population of new plaques. These clus-
ters of newly developed plaques suggest that once a new 
plaque has formed, subsequent new plaques cluster in the 
vicinity of this original new plaque. However, the tempo-
ral resolution of the method used here does not allow for 
this distinction. A third reason is the use of Methoxy-XO4. 
Although it has been shown that Methoxy-XO4 labels dense 
core plaques in vivo [6, 7, 13, 16, 17, 20, 31] and that it 
does not lose its staining capacity over long periods (up to 
90 days) [9], we cannot rule out the possibility that it contin-
ues to label new plaques for some time after the initial appli-
cation. Therefore, some plaques could be counted as pre-
existing, although they appeared later and hence are actually 
new plaques. These three arguments support the notion that 
our method underestimates the amount of ‘new in vicinity’ 
plaques, implying that there may actually be many more 
newly emerged plaques in the vicinity of a pre-existing 
plaque. Another explanation for less close new plaques in 
animals with higher plaque density could be microglia that 
are recruited to the plaques [24] and take up Aβ material 
[6]. Therefore, new plaques would be less likely to form in 
the vicinity of pre-existing plaques in animals with a high 
plaque density and more peri-plaque microglia.
Our finding that plaques form preferentially in the 
vicinity of pre-existing plaques raises the question which 
mechanism might cause the formation of new plaques in 
the peri-plaque region. There is evidence that plaques can 
be induced by a seeding agent [22] and so it may be that 
pre-existing plaques produce seeds via diffusion or degrada-
tion processes, which induce the formation of neighboring 
plaques or represent a ‘pool’ of various Aβ conformations 
that further contribute to local toxicity and facilitate plaque 
formation [8, 11, 15, 18, 23]. One way in which plaques can 
exert this local toxicity is by the release of reactive oxygen 
species [21] resulting in oxidative stress on the surround-
ing cells which distorts neurites [10] and contributes to a 
decrease in membrane integrity in the vicinity of plaques 
[26]. Following initial plaque deposition, an immune 
response is triggered [24], which could be detrimental to the 
micro-environment [6] and increase the amount of plaque 
forming agents released from damaged neurons and glia. 
The micro-environment in which the initial plaque devel-
oped may be particularly favorable for additional plaque 
development [3, 4] so that multiple plaques preferentially 
develop within a very small area. Any or all of these factors 
could contribute to the non-random deposition of plaques in 
the vicinity of a pre-existing plaque.
Another important outcome of our study is the identi-
fication of multicored plaques. We observed many multi-
cored plaques that clearly descended from more than one 
initial core. This emphasizes the clustering concept of large 
plaque formation since these plaques had to originate from 
a cluster of smaller precursors. We also found that the more 
Fig. 7  Schematic illustrating the clustering of amyloid plaque devel-
opment. The initial plaque formation (a) can be followed by the for-
mation of a new plaque close by b. These two plaques can merge 
over time (c) to form one large plaque with a single plaque core (d) 
or rather remain separate (e) as part of a larger plaque with multi-
ple cores (g). Alternatively, the initial plaque (a) is followed by the 
clustering of new plaques around the initial plaque (f, flower plaque) 
and ultimately this cluster can merge together giving rise to one large 
plaque with multiple cores (g). Solid arrows refer to events captured 
by our data. The dashed arrow represents hypothetical plaque devel-
opment
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cores a plaque has, the larger it tends to be, indicating that 
large plaques can be formed from many neighboring small 
plaques that developed over time. After 4 months post-
injection, we observed different fates for these multicored 
plaques: they either stay separate but embedded within 
diffuse Αβ material or merge together to form a single large 
dense core. The idea of dense core plaque fusion is sup-
ported by previous work using a different mouse model of 
AD that reported the merger of several Methoxy-XO4 posi-
tive plaque cores over time [9]. Taken together, our results 
demonstrate the clustering of plaques and the subsequent 
merger of plaque clusters as a mechanism of large plaque 
formation.
Although the use of only one mouse model of AD is an 
important caveat to bear in mind, we believe that our results 
could pertain to a general mechanism of plaque growth. 
Our data suggest that a uniform growth of plaques from a 
single seed may provide only a partial explanation of how 
large plaques develop over time and rather complements a 
uniform growth model of plaque development by adding a 
new clustering dimension. We propose a multi-faceted clus-
tering mechanism whereby new plaques can deposit close 
to existing plaques forming a cluster of small plaques. This 
cluster can then ultimately merge over time to give rise to 
the single, large plaques that we observe in aged mice and 
autopsy material of AD patients. The clustering hypoth-
esis as a mechanism of plaque formation and growth sug-
gests that the micro-environment becomes conducive to 
plaque deposition. Whether this is the first plaque lead-
ing to a greater chance of another plaque forming nearby 
or a reflection of something unique in that microenviron-
ment that leads to both the first deposit and the increased 
chance of subsequent deposits remain uncertain. In either 
case, these observations of plaque development deepen our 
understanding of plaque formation and plaque growth in 
Alzheimer’s disease.
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